1-3 of 3
Edward C Bradley, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Ruben A. Mesa, MD, Jorge Cortes-Franco, MD, Animesh D. Pardanani, MBBS, PhD, Deborah A. Thomas, MD, Zeev Estrov, MD, Edward C Bradley, MD, Susan Erickson-Viitanen, PhD, Kris Vaddi, Ph.D., Richard Levy, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2009) 114 (22): 756.
https://doi.org/10.1182/blood.V114.22.756.756
Published: 2009
Journal Articles

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro Vannucchi
Journal: Blood
Blood (2009) 114 (22): 311.
https://doi.org/10.1182/blood.V114.22.311.311
Published: 2009
Journal Articles

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Timothy Burn, PhD, Kris Vaddi, PhD, DVM, John Redman, MD, Edward C Bradley, MD, Richard Levy, MD, Steven Friedman, MD, Gregory Hollis, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 2802.
https://doi.org/10.1182/blood.V112.11.2802.2802
Published: 2008